HomeEczemaDupilumab Conjunctivitis

Related Post

Dupilumab Conjunctivitis

- Advertisement -
- Advertisement -

Dupilumab conjunctivitis is a condition that affects the eyes. It is characterized by inflammation of the conjunctiva, which is the thin layer of tissue that covers the white part of the eye and lines the inside of the eyelids. The condition can be caused by allergies or other irritants, but it often occurs in people who are taking dupilumab, an immunosuppressive medication used to treat conditions like asthma and eczema. Symptoms of dupilumab conjunctivitis include redness, itching, burning, tearing, and swelling of the eyes. Treatment typically involves using artificial tears or antihistamines to relieve symptoms. In severe cases, corticosteroids may be necessary.

Dupilumab (trade name Dupixent) is a human monoclonal antibody that targets interleukin-4 receptor alpha (IL-4Ra), used to treat atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. It was developed by Sanofi and Regeneron. In March 2017, the U.S. Food and Drug Administration (FDA) approved dupilumab for use in adults with moderate-to-severe eczema who are not responding to other treatments.[1][2] The FDA granted approval of dupilumab for children aged 12 years or older in March 2019.[3]

Common side effects include injection site reactions, cold sores/herpes simplex virus infections around the mouth, headache,[1] high blood pressure,[1][2] eye inflammation including conjunctivitis and keratitis;[1][2] These usually improve after stopping treatment.[1] Serious side effects may include skin cancer or serious allergic reactions such as anaphylaxis; both occur rarely (<0.01% of people).[1][2]:8 Use during pregnancy may harm the baby; it is unknown if use while breastfeeding harms the baby.[4][5] It is a selective blocker of IL-4 signaling via IL-4Rα found on antigen-presenting cells which inhibits type 2 helper T cell activity involved in airway remodeling seen in asthmatics as well as reducing the production of IgE antibodies by B cells thought to be responsible for aggravating atopic dermatitis symptoms through mastocytosis activation..[6]. Dupiliumab was created using phage display technology resulting from a partnership between Curis Inc., Massachusetts Institute of Technology, and Harvard Medical School leading to co-ownership Patent rights currently shared among holders Sanofi(62%), Regeneron(38%)

Dupixent works by inhibiting overactive Type 2 helper T cells which play a role n airway remodeling seen n asthmatics. It also reduces the production 0f lgE antibodies y b Cells thus alleviating symptoms related t0 mastocytosis like those experienced y patients with atopic dermatitis. The drug has been shown to e effective when given intravenously r subcutaneously every two weeks once weekly intramuscularly.


  • Zlina Kozan

    I wanted to create such a page as I have been dealing with dyshidrotic eczema for a long time. On this page, I researched what came to my mind about dyshidrotic eczema and I will share the results with you. The information on this page is not treatment advice. Please consult your doctor first.

Previous article
Next article

Latest Post